세계의 인간 DNA 백신 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 투여 경로별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Human DNA Vaccine Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Route of Administration, By Application, By End User, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,169,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,541,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 10,968,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

인간 DNA 백신 세계 시장은 2024년에 3억 4,544만 달러로 평가되었으며, 2030년에는 5억 2,399만 달러에 이를 것으로 전망됩니다. CAGR 7.15%로 성장할 것으로 예측됩니다.

이 시장은 유전공학의 진보, 헬스케어 분야에 대한 투자 증가, 최첨단의 치료 및 예방 솔루션에 대한 수요 증가에 힘입어 강력한 성장을 이루고 있습니다. 이 백신들은 향상된 안전성 프로파일, 짧은 개발 일정, 그리고 다양한 질병에 걸친 적응력으로 돋보입니다. 다이나믹한 백신 산업 속에서 DNA 백신 시장은 끊임없는 기술 혁신, 임상 응용의 확대, 세계의 보건상의 우선사항의 고조에 의해 급속한 진화를 이루고 있습니다. 규제 트렌드에 맞춰 배송 기술을 혁신하는 기업들은 상당한 경쟁 우위를 점할 것으로 예상됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	3억 4,544만 달러
시장 규모 : 2030년	5억 2,399만 달러
CAGR : 2025-2030년	7.15%
급성장 부문	근육 내
최대 시장	북미

시장 성장 촉진요인

감염 및 만성 질환의 유병률 증가

주요 시장 과제

제한적인 임상 성공 및 규제 당국의 승인

주요 시장 동향

플랫폼 기반 백신 기술로의 전환

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 인간 DNA 백신 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 투여 경로별(근육내, 피하, 피내, 기타)
  • 용도별(종양학, 결핵, HIV, 기타)
  • 최종 사용자별(병원 및 클리닉, 바이오테크놀러지·제약기업, 학술기관 및 연구기관, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 인간 DNA 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 인간 DNA 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 인간 DNA 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 인간 DNA 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 인간 DNA 백신 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 세계의 인간 DNA 백신 시장 : SWOT 분석

제14장 경쟁 구도

• BOEHRINGER INGELHEIM GmbH(Merial)
• ELI-LILLY(Novartis Animal Health)
• Gene One Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals(VGX Animal Health)
• Genexine, Inc.
• VIATRIS INC.(Rottapharm Biotech)
• Takara Holdings(Takara Bio)
• ZOETIS INC.(Fort dodge Animal Health)
• Zydus Lifesciences Limited

제15장 전략적 제안

제16장 기업 소개와 면책사항

SHW

영문 목차

영문목차

The Global Human DNA Vaccine Market was valued at USD 345.44 million in 2024 and is projected to reach USD 523.99 million by 2030, growing at a CAGR of 7.15%. This market is undergoing robust growth fueled by advancements in genetic engineering, increased investment in the healthcare sector, and heightened demand for cutting-edge therapeutic and preventive solutions. DNA vaccines operate through the direct delivery of engineered plasmid DNA encoding specific antigens, stimulating precise immune responses. These vaccines stand out for their enhanced safety profile, shorter development timelines, and adaptability across a broad spectrum of diseases. Positioned within the dynamic vaccine industry, the DNA vaccine market is poised for rapid evolution driven by continuous technological breakthroughs, expanded clinical applications, and heightened global health priorities. Companies that align with regulatory trends and innovate in delivery technologies are expected to gain significant competitive advantages.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 345.44 Million
Market Size 2030	USD 523.99 Million
CAGR 2025-2030	7.15%
Fastest Growing Segment	Intramuscular
Largest Market	North America

Key Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The escalating occurrence of both infectious and chronic diseases is a critical driver for the Global Human DNA Vaccine Market. In 2021, approximately 18 million people died prematurely from noncommunicable diseases (NCDs), with 82% of these deaths occurring in low- and middle-income countries (LMICs), underscoring the disproportionate impact on economically disadvantaged regions. Furthermore, LMICs accounted for 73% of all NCD-related deaths globally. This significant health burden amplifies the need for innovative vaccination approaches like DNA vaccines, which are gaining momentum due to their unique benefits. Notably, in 2023, about 1.3 million people contracted HIV worldwide, a 39% reduction in new cases from 2010, indicating a global infection rate of 0.17 per 1,000 uninfected individuals. As diseases such as HIV, Hepatitis, Tuberculosis, HPV, COVID-19, Zika, and Ebola continue to challenge public health systems, DNA vaccines offer scalable, adaptable, and long-lasting immune protection-traits that are increasingly in demand globally.

Key Market Challenges

Limited Clinical Success and Regulatory Approvals

Despite encouraging outcomes in preclinical stages, human DNA vaccines face challenges in achieving strong clinical efficacy. A primary obstacle is their lower immunogenicity in humans when compared to traditional vaccine types, which often leads to suboptimal immune responses in clinical settings-especially when conventional administration methods are used. Consequently, regulatory approval for human use remains limited, with most authorizations to date focused on veterinary applications. Although the pandemic has accelerated interest in DNA vaccines for humans, regulatory bodies continue to require comprehensive data on long-term safety and efficacy. These stringent and often uncertain regulatory demands present a substantial hurdle, particularly for smaller biotech firms, thereby slowing commercial progress and investment in the field.

Key Market Trends

Shift Toward Platform-Based Vaccine Technologies

The vaccine sector is witnessing a strong trend toward platform-based technologies, which leverage a unified system for developing multiple vaccines. DNA vaccine platforms exemplify this model. By standardizing delivery mechanisms, production processes, and clinical trial protocols, these platforms significantly cut down on development time and costs. They also enable rapid responses to emergent health threats, supporting quicker vaccine rollouts. Pharmaceutical companies and investors are increasingly attracted to this scalable framework, which not only fosters efficient product pipelines but also strengthens pandemic preparedness strategies. These systems support diverse disease applications, enhance public-private collaborations, and draw funding from global health stakeholders.

Key Market Players

• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• Gene One Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Genexine, Inc.
• VIATRIS INC. (Rottapharm Biotech)
• Takara Holdings (Takara Bio)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Lifesciences Limited

Report Scope:

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human DNA Vaccine Market, By Route of Administration:

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Human DNA Vaccine Market, By Application:

• Oncology
• Tuberculosis
• HIV
• Others

Human DNA Vaccine Market, By End User:

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Human DNA Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human DNA Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
  • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Human DNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human DNA Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Human DNA Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Human DNA Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human DNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Human DNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Human DNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Human DNA Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Human DNA Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human DNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Human DNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Human DNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Human DNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Human DNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human DNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Human DNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Human DNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human DNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Human DNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human DNA Vaccine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. BOEHRINGER INGELHEIM GmbH (Merial)
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. ELI-LILLY (Novartis Animal Health)
• 14.3. Gene One Life Science
• 14.4. GEOVAX LABS, INC
• 14.5. Inovio Pharmaceuticals (VGX Animal Health)
• 14.6. Genexine, Inc.
• 14.7. VIATRIS INC. (Rottapharm Biotech)
• 14.8. Takara Holdings (Takara Bio)
• 14.9. ZOETIS INC. (Fort dodge Animal Health)
• 14.10.Zydus Lifesciences Limited

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료